Virginiamycin
Also known as: Bactocill, Eskalin, Stafac, Streptogramin A/B mixture, Virginiamycin M1, Virginiamycin M1 + S1, Virginiamycin S1, VM
Source Virginiamycin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Virginiamycin is a mixture of two streptogramin antibiotics (type A and type B) that together inhibit bacterial protein synthesis. It is primarily employed as an oral growth‑promoting feed additive in food‑producing animals, and its potent activity against certain Gram‑positive pathogens has prompted investigation of its use in human medicine as a last‑resort antibiotic.
Mechanism of Action
The type‑A component (virginiamycin M) binds the peptidyl‑transferase centre of the bacterial 50S ribosomal subunit, blocking both the aminoacyl‑tRNA entry at the A‑site and peptide‑bond formation at the P‑site. This prevents elongation of the nascent peptide chain. When combined with the type‑B component, the two agents act synergistically, producing an irreversible inhibition of ribosomal function and a bactericidal effect.
What the Research Shows
Animal studies have shown that the use of virginiamycin as a growth promoter selects for vancomycin‑, gentamicin‑ and quinupristin/dalfopristin‑resistant Enterococcus spp., raising concerns about resistance gene transfer to humans (Hammerum et al., 2010). Molecular work clarified that the type‑A component disrupts donor and acceptor sites of peptidyl‑transferase, while type‑B agents act at the base of the 50S central protuberance, together yielding a >100‑fold increase in potency (Di Giambattista et al., 1989; Mast & Wohlleben, 2014). Comparative reviews of related streptogramins (e.g., quinupristin/dalfopristin) note strong in‑vitro activity against resistant Gram‑positives and a favorable post‑antibiotic effect, but clinical efficacy remains to be fully established (Chant & Rybak, 1995). Epidemiologic surveys document the emergence of virginiamycin resistance among both animal and human isolates (Thal & Zervos, 1999). Overall, the literature supports potent antibacterial activity but highlights resistance concerns and limited human clinical data.
Reported Benefits
In vitro studies demonstrate that virginiamycin, especially when combined with its type‑B partner, exhibits strong activity against a range of Gram‑positive bacteria, including strains resistant to other agents. Its oral administration in livestock improves feed efficiency and growth rates. The synergistic mechanism provides bactericidal effects that are greater than those of the individual components, making it a valuable tool in veterinary antimicrobial programs.
Limitations of the Evidence
Widespread use in animal agriculture has been linked to the selection of multidrug‑resistant enterococci, which may act as reservoirs of resistance genes for human pathogens. Human clinical data are sparse; most efficacy evidence comes from in‑vitro or animal models. The regulatory status for human therapeutic use is unclear, and further trials are needed to confirm safety and effectiveness in patients.
Safety Considerations
Direct safety data for virginiamycin in humans are lacking. The principal concern is ecological: its use in food animals can promote the spread of resistant bacteria to humans via the food chain. Related streptogramin products have been associated with mild injection‑site irritation, but no specific adverse events for oral virginiamycin have been reported in the cited literature.
How It Is Administered
Virginiamycin is administered orally, typically incorporated into animal feed as a growth‑promoting additive. No formulation details for human use are provided in the available sources.
Routes of Administration
Goals & Uses
- Gram-positive bacterial infection treatmentAntimicrobialLow
- Prevention of necrotic enteritis in poultryVeterinary / Infectious DiseaseModerate
- Prevention of bacterial enteric infections in animalsVeterinaryModerate
- Growth promotion in livestockVeterinary / AgriculturalModerate
Contraindications
- Pregnant or lactating animalsReproductiveModerate
- Known hypersensitivity to streptograminsAllergyHigh
- Human therapeutic useRegulatory/safetyHigh
Adverse Effects
- Residue accumulation in food productsFood SafetyUnknown
- Selection for streptogramin-resistant enterococci (VRE)Antimicrobial ResistanceUnknown
- DiarrheaGastrointestinalCommonLoose or frequent stools
- Gastrointestinal upset (in treated animals)GastrointestinalUncommon
- Selection of resistant bacteriaMicrobialCommon
Drug Interactions
- Other protein synthesis inhibitorsModerate
- Quinupristin/dalfopristin (Synercid)High
Population Constraints
- Humans (general)Regulatory / SafetyAbsolute
- EU livestockGeographic / RegulatoryAbsolute
- Human patientsClinicalAbsolute
- Organic-certified livestock operationsAgricultural RegulatoryAbsolute
Regulatory Status
- European UnionWithdrawnBanned for use in animal feed due to resistance concerns.
- United StatesWithdrawnNo longer approved for use as a growth promoter; not approved for human medicine.
- United KingdomWithdrawnSame as EU.
Withdrawn or not approved for human use in the US and EU; historically approved for veterinary use but many jurisdictions have restricted or banned its use as a growth promoter due to antimicrobial resistance concerns.
Evidence & Sources
- Journal ArticleModerateHammerum AM, Lester CH, Heuer OE2010-01-01T00:00:00.000000Z
- Journal ArticleModerateDi Giambattista M, Chinali G, Cocito C1989-01-01T00:00:00.000000Z
- Journal ArticleModerateMast Y, Wohlleben W2014-01-01T00:00:00.000000Z
- Journal ArticleModerateChant C, Rybak MJ1995-01-01T00:00:00.000000Z
- Journal ArticleModerateThal LA, Zervos MJ1999-01-01T00:00:00.000000Z
Frequently Asked Questions
What type of bacteria does virginiamycin target?
Virginiamycin primarily inhibits Gram‑positive bacteria by binding the 50S ribosomal subunit and blocking protein synthesis. It is active against many Enterococcus and Staphylococcus strains, including some that are resistant to other antibiotics.
Why is virginiamycin used in livestock?
In animal production, oral virginiamycin improves feed efficiency and growth rates. Its antibacterial activity helps control subclinical infections, supporting healthier and faster‑growing livestock.
Is virginiamycin safe for human use?
Human safety data are limited. The main concern is the potential for resistance genes to spread from animals to humans. More clinical studies are required before it can be recommended for human therapy.
How does the combination of two components improve efficacy?
Each component alone is only modestly bacteriostatic. When combined, they bind distinct sites on the ribosome, producing a synergistic effect that can be up to a hundred times more potent and bactericidal.
Can virginiamycin cause antibiotic resistance?
Yes. Use of virginiamycin in food animals has been linked to the emergence of resistant Enterococcus strains, which may transfer resistance genes to human pathogens, highlighting the need for prudent use.
What is Virginiamycin?
Virginiamycin is a mixture of two streptogramin antibiotics (type A and type B) that together inhibit bacterial protein synthesis. It is primarily employed as an oral growth‑promoting feed additive in food‑producing animals, and its potent activity against certain Gram‑positive pathogens has prompted investigation of its use in human medicine as a last‑resort antibiotic.
What is Virginiamycin used for?
Virginiamycin is educationally associated with: Gram-positive bacterial infection treatment, Prevention of necrotic enteritis in poultry, Prevention of bacterial enteric infections in animals, Growth promotion in livestock. Educational only — not medical advice.
How is Virginiamycin administered?
Recorded routes of administration: Oral.
What are the potential side effects of Virginiamycin?
Reported adverse effects include: Residue accumulation in food products, Selection for streptogramin-resistant enterococci (VRE), Diarrhea, Gastrointestinal upset (in treated animals), Selection of resistant bacteria. This list is not exhaustive — consult a qualified clinician.
Who should avoid Virginiamycin?
Recorded contraindications: Pregnant or lactating animals, Known hypersensitivity to streptogramins, Human therapeutic use. Consult a qualified clinician before use.